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Simple Summary: Craniofacial development is an intricate and delicate process in normal embryo-
genesis requiring spatiotemporal release of various mediators/proteins that provide communication
between different cell/tissue types, like epithelial cells, connective tissue, and endothelial cells. If
this sequence is impaired or blocked due to genetic or environmental factors, it can lead to clefting.
A cleft is an abnormal space or gap in the upper lip, alveolus, or palate that occurs due to failure
of completion of fusion processes in the midline during facial development. Previous studies have
identified various genetic factors (genes) that can lead to clefting. The most promising candidates
amongst them are FGF/FGFR (fibroblast growth factor/FGF receptor) signaling genes and FOX (fork-
head box protein) genes. We investigated the expression of these genes in tissue material obtained
from cleft-affected patients. Our results indicate that these genes profoundly affect the pathogenesis
and manifestation of clefts, especially by enhancing local site inflammation and fibrosis. Further, they
play a vital role in angiogenesis, apoptosis, and cell proliferation.
Abstract: Orofacial clefts affect hundreds of thousands of children worldwide annually and are
usually corrected by a series of surgeries extending to childhood. The underlying mechanisms that
lead to clefts are still unknown, mainly because of the multifactorial etiology and the myriad of
interactions between genes and environmental factors. In the present study, we investigated the role
and expression of candidate genes belonging to the FGF/FGFR signaling pathway and FOX family in
tissue material obtained from 12 pediatric patients undergoing cleft correction surgery. The expression
was investigated using immunohistochemistry (IHC) and chromogenic in-situ hybridization (CISH)
in three cell/tissue types—epithelial cells, connective tissue, and endothelial cells. We found elevated
expression of FGFR1 in epithelial cells while no expression was observed in endothelial cells. Further,
our results elucidate the potential pathogenetic role of FGFR1 in cellular proliferation, local site
inflammation, and fibrosis in cleft patients. Along with bFGF (also called FGF2), FGFR1 could play
a pro-inflammatory role in clefts. Over-amplification of FGFR2 in some patients, along with bFGF,
could potentially suggest roles for these genes in angiogenesis. Additionally, increased expression of
FOXE1 (also called TTF2) contributes to local site inflammation. Finally, zero to low amplification of
FOXO1 could suggest its potential role in inducing oxidative stress in the endothelium along with
reduced epithelial apoptosis.
Keywords: cleft palate; cleft lip; immunohistochemistry; in-situ hybridization; inflammation;
FGF/FGFR; FOXE1; FOXO1
1. Introduction
Congenital cleft lip and palate is one of the most commonly reported birth defects,
affecting hundreds of thousands of children worldwide [1]. A cleft is defined as an abnormal
space or gap in the upper lip, alveolus, or palate that occurs due to failure of completion of
fusion processes in the midline during facial development [2]. Orofacial clefts have been
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reported to occur as isolated cases or as associated manifestations in over 500 recognized
Mendelian syndromes (Online Mendelian Inheritance in Man (OMIM), www.ncbi.nlm.nih.
gov/omim/, accessed on 25 March 2021).
Due to its complex etiology, clinical manifestations of clefting are not limited to only
dental complications but also encompass speech difficulties, ear infections, feeding prob-
lems, as well as behavioral complications [3]. The treatment of such patients, naturally, is
also complex, multidisciplinary, long term, exhaustive (both mentally and physically), and
generally involves multiple phases of surgical intervention [2,4]. To achieve the optimum
results, both in terms of aesthetic restoration and functional normality, it is extremely im-
portant that the surgical care is provided at the right age and right time of development [5].
The process of palatogenesis (embryonic development of lip and palate) is a multistep
process that begins at the fourth gestational week [6]. It is a very tightly regulated sequalae
of events that involves the development, maturation, and fusion of facial processes in
the midline [6]. For this fusion to occur, the bilateral palatal shelves must grow beside
the tongue and then elevate towards the midline to form the medial edge epithelium
(MEE) [7,8]. This is followed by degeneration of the MEE and disappearance of the midline
epithelial seam [9]. This programmed cell death of MEE is mediated by the mesenchymal
cells (embryonic connective tissue), which ensure that a continuity can be established
across the horizontal plate [7]. The mesenchyme in the palate traces its origin to the
cranial neural crest (CNC) cells, a subset of neural crest cells (NCCs). During craniofacial
development, CNC cells migrate from the lateral ridges of the neural plate to branchial
arches [8]. Similarly, part of the epithelium in the palate traces its origin to pharyngeal
ectoderm-derived epithelial cells [8,10].
The crosstalk (mediated by cytokines) between the epithelium and the mesenchyme
is crucial for normal palatogenesis (especially for degeneration of the MEE) and any
disruption in the mesenchyme–epithelial crosstalk eventually leads to clefts of varying
severity [6–10]. The crosstalk can be disrupted by various genetic and environmental
factors, like maternal smoking, nutrition, alcohol consumption, and so on. Further, defects,
either in facial mesenchyme patterning, growth or in epithelium fusion, also result in cleft
palate [8]. Occasionally, a fibrous band, known as Simonart’s band, is observed attached to
the cleft, suggesting that occlusive epithelial adhesions can also result in clefting [11].
Therefore, it is imperative to study the genes/pathways that regulate or control this
crosstalk during palatogenesis in order to completely understand the underlying patho-
genesis. Many candidate genes have been suggested to play a role in crosstalk (directly or
indirectly) and carry mutations in patients with non-syndromic clefts. While the roles of
genes like IRF6 (interferon regulatory factor 6) [12,13] and VAX1 (ventral anterior home-
obox 1) [14,15] have been confirmed after extensive research, the roles of other genes
are yet to be fully substantiated and confirmed. Other promising candidates include the
FGF (fibroblast growth factor) signaling family genes [16–18], FOX (forkhead box protein)
family genes [19,20], MSX1 (msh homeobox 1) [21,22], and BMP4 (bone morphogenetic
protein 4) [23].
The FGF family includes 18 members that mediate their actions via four distinct recep-
tors (FGFRs). These receptors show differential binding properties and, upon activation,
regulate various cellular processes such as cell proliferation, differentiation, apoptosis, and
mobility [24,25]. The FGF/FGFR family plays a vital role in maintenance of bone home-
ostasis and mutations in these genes are associated with various congenital bone diseases,
including chondrodysplasia syndromes, craniosynostosis syndromes, and syndromes with
dysregulated phosphate metabolism [25,26]. FOX family genes, on the other hand, consist
of transcriptional regulators, divided into 19 classes from FOXA to FOXS [11], which are
involved in the development of various organs, regulation of senescence or proliferation,
and metabolic homeostasis [27].
Due to their crucial roles in mesenchymal–epithelial crosstalk and in overall cran-
iofacial development, in the present study we investigated the expression and role of
FGF/FGFR signaling pathway genes and the FOX family genes in orofacial clefts. Further,
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we investigated the expression of these genes in different tissues/cells—epithelial cells,
connective tissue, and endothelial cells. Finally, we investigated their possible roles in
subsequent local inflammation, along with possible gene–gene interactions and the role
of environmental factors, to allow for better understanding, prediction, and diagnosis of
clefts, as well as better treatment modalities.
2. Materials and Methods
2.1. Profile of Study Participants
In the present study, tissue samples were obtained from 12 pediatric patients (10
male children and 2 female children) who presented for consultation and treatment at
the Department of Oral and Maxillofacial Surgery, Institute of Stomatology, Riga Stradin, š
University (RSU), Latvia. The tissue for all patients was collected from the site of clefting
by the same surgeon. The study was approved by the Research Ethics Committee (REC)
of RSU with the approvals dated 22 May 2003, 17 January 2013, and 28 June 2018, in
accordance with the 1975 Helsinki Declaration (as revised in 2008). Written informed
consent was obtained from all patients (given by the parents) for participation in the study
and publication of the study data.
Children in the study were aged between 3 and 18 months at the time of tissue collec-
tion and were scheduled for plastic surgery of either bilateral or unilateral clefts. None of
the children were previously diagnosed with coexisting genetic syndromes, chromosomal
abnormalities, or immune deficiencies. Briefly, mothers of two infants were reported to
have threats of miscarriage in pregnancy; two other infants were reported to have parents
with histories of smoking; three infants had mothers who used paracetamol in pregnancy
and two infants presented with family histories of genetic disorders (however, the children
were not affected). Table 1 summarizes the clinical information of the patients.




(in Months) Gender Clinical Diagnosis * Material Collected Remarks
1 3.5 M Cheilognathouranoschisis sinistra Lipmucosa
Mother reported use of paracetamol
during pregnancy; father was smoker and
partially alcoholic. Epilepsy in the family
tree. Child was born overweight.
2 4 M Cheilognathouranoschisis sinistra Lipmucosa
There was a reported threat of miscarriage
in the 36th gestational week; history of
clefts in the family tree.
3 4 F Cheilognathouranoschisis dextra Lipmucosa -
4 4 F Cheilognathouranoschisis sinistra Lipmucosa
Born in the 42nd gestational week; mother
reported use of paracetamol
during pregnancy.
5 4 M Cheilognathouranoschisis sinistra Lipmucosa
Born in the 41st gestational week; mother
reported use of paracetamol
during pregnancy.
6 4 M Cheilognathouranoschisis dextra Lipmucosa
History of arrhythmogenic right
ventricular dysplasia (ARVD) during the
first trimester; mother reported use of
Neuromidin, Ibumetin, and Theraflu.
7 4.5 M Cheilognathouranoschisis sinistra Lipmucosa
History of Down syndrome in the family
tree.
8 5 M Cheilognathouranoschisis sinistra Lipmucosa
History of clefts in the family tree; mother
reported use of Amoxiclav
during pregnancy.





(in Months) Gender Clinical Diagnosis * Material Collected Remarks
9 8 M Cheilognathouranoschisis sinistra Lipmucosa Both parents were regular smokers.
10 13 M Cheilognathouranoschisisbilateralis
Lip
mucosa
The child had multiple anomalies,
including heart failure.
11 4 M Cheilognathouranoschisis sinistra Vomermucosa
History of heavy toxicosis during the
pregnancy; there was a threat of
miscarriage in the 36th gestational week.
12 18 M Cheilognathouranoschisis sinistra Vomermucosa
Mother was reported to suffer from high
emotional stress.
* Clinical diagnosis is provided in Latin; cheilognathouranoschisis—cleft lip, alveolar ridge, and palate; sinistra—left; dextra—right;
bilateralis—bilateral.
2.2. Data and Sample Collection
Tissue samples were collected immediately after the plastic surgery and fixed for
a day in a mixture of 2% formaldehyde and 0.2% picric acid in 0.1 M phosphate buffer
(pH 7.2). Next, the samples were rinsed in Tyrode buffer (content: NaCl, KCl, CaCl2·2H2O,
MgCl2·6H2O, NaHCO3, NaH2PO4·H2O, glucose) containing 10% saccharose for 12 h
followed by paraffin embedment. Samples were registered and assigned randomized
sequence tags. Patient identity was not disclosed at any time to the researchers and/or lab
assistants, in accordance with protocol. Only patient history (as shown in Table 1) was kept
with the sequence tags.
2.3. Routine Histological Investigation
In accordance with standard laboratory procedures, 3–4 µm of serial tissue sections
were prepared from the solidified paraffin block for histological staining and immunohisto-
chemistry (IHC). Tissue sections placed on the slides were kept at 56 ◦C for 20–60 min in a
thermostat. De-paraffinization of the sections was undertaken using xylene solution and
96% ethanol alcohol. Hematoxylin and eosin staining (Mayer’s; Bio Optica Milano, Milan,
Italy) was undertaken using standard procedure.
Slides were dehydrated with ethanol and clarified with carboxylol and xylene. Finally,
a drop of histological Pertex glue (Histolab Products AB, Askim, Sweden) was applied
and slides were covered with a cover glass. Slides were visualized using brightfield light
microscopy with a Leica DC 300F camera microscope (Leica DM500RB; Leica Biosystems
Richmond, Richmond, IL, USA).
2.4. Immunohistochemistry (IHC)
De-paraffinized, washed, and cleared tissue sections were rinsed with TRIS buffer
(Diapath, Martinengo, Italy) for 10 min followed by boiling in EDTA buffer in a microwave
for 10 min. The tissue samples were cooled to 65 ◦C and then placed again in TRIS wash
buffer. Endogenous peroxidase was blocked with 3% peroxidase (Dako, Naestved, Den-
mark). FGF basic (ab16828, working dilution 1:200, rabbit, Abcam, Cambridge, UK), FGFR1
(orb38277, working dilution 1:50, rabbit, Biorbyt Limited, Cambridge, UK), and FOXE1
(ab5080, working dilution 1:500, goat, Abcam, Cambridge, UK) antibodies were used for
biotin–streptavidin immunohistochemistry.
All antibodies were diluted with antibody diluent (Cell MarqueTM, Rocklin, CA, USA).
Incubation with primary antibody was performed for 2 h followed by washing in TRIS wash
buffer. The HiDef DetectionTM HRP polymer system (Cell MarqueTM, Rocklin, CA, USA)
was used for rabbit antibodies as per the manufacturer’s guidelines. The ImmunoCruzTM
ABC staining system was used for goat antibody (Santa Cruz Biotechnology, Dallas, TX,
USA) as per the manufacturer’s guidelines. Tissue sections were incubated with biotin-
containing secondary antibody for 30 min and rinsed again for 10 min in TRIS wash buffer,
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followed by another round of incubation and washing with biotin-containing tertiary
antibody and TRIS wash buffer.
The tissue sections were then coated with the DAB+ chromogenic liquid using a DAB
Substrate Kit (Cell MarqueTM, Rocklin, CA, USA) and incubated at room temperature
for up to 10 min to obtain brown staining of immunoreactive structures. The sections
were then washed in distilled water and contrast-stained with hematoxylin for 2 min. The
antibody-treated tissue material was dehydrated with ethanol solutions and clarified with
carboxylol and xylene. The slides were prepared and viewed under a light microscope (as
described previously). Negative and positive IHC controls were prepared for each sample
in the study.
2.5. Chromogenic In-Situ Hybridization (CISH)
CISH is a relatively new technique that utilizes a chromogen-labeled DNA probe
which is often visualized using peroxidase reaction. The technique is based on the principle
of subtractive hybridization. The technique allows for simultaneous assessment of tissue
morphology and CISH signals and is standardized with complete kits, thereby eliminating
the need to perform the more expensive fluorescent microscopy [28,29]. Due to easy
interpretation of results and the technique’s superiority when compared with IHC, we
decided to detect the signals of the candidate genes using CISH.
CISH was performed using ZytoDot 2C CISH Implementation Kit (ZytoVision GmbH,
Bremerhaven, Germany). Probes of FGFR1, FGFR2, and FOXO1 were used in this study.
Pretreatment was performed using standard laboratory methods. Denaturation and hy-
bridization were undertaken using 10 µL of each probe placed on each pretreated specimen
with a pipette. Slides were covered with an 18 mm × 18 mm coverslip and placed on a hot
plate for 5 min at 79 ◦C, then transferred to a humidity chamber and hybridized overnight
at 37 ◦C.
To proceed with the detection process, the coverslips were removed by submerging the
slides in SSC wash buffer followed by TBS wash buffer. Then, the slides underwent the next
steps in the CISH procedure as per the manufacturer’s guidelines. Slides were transferred
into a staining jar and washed for 2 min under cold running tap water. Dehydration
was undertaken with 100% ethanol and the slides were then incubated in xylene. The
coverslips were re-attached while avoiding air bubbles and the slides visualized under a
light microscope.
Under the microscope, red-colored dots indicated control, whereas green-colored dots
indicated target. After counterstaining the nucleus with a nuclear dye, hybridized probe
fragments were visualized. Two signals per probe were expected to appear in the cell nuclei
of normal cells in interphase or metaphase or in the nuclei of cells without aberrations in
the examined chromosomes.
2.6. Visualization and Statistical Analysis
The images obtained using microscopy were analyzed with Image Pro Plus 6.0 (Media
Cybernetics, Rockville, MD, USA). Cells with nucleus/cytoplasm marked brown in the
IHC reaction were considered as immunoreactive, i.e., as showing immunopositivity. For
CISH, the signals from the green probes in the cells/nuclei were evaluated. Epithelium,
Connective Tissue, and wall of mucosal microcirculation blood vessels (i.e., Endothelium)
were assessed. Semi-quantitative counting was undertaken by two independent morphol-
ogists in at least five randomly selected vision fields, each at 400× magnification, for
each tissue section in order to quantify the immunoreactive and probe-containing cells
(Table 2) [30,31].
Statistical analysis was performed using non-parametric Kruskal–Wallis ANOVA
with appropriate post hoc tests and Bonferroni correction for inter-group comparison.
Spearman’s Rho was used for correlation analysis. The data were stored and analyzed
using MS Excel (MS Office 365) and SPSS v26.0 (IBM Corp., Armonk, NY, USA). For
statistical analysis, the numbers of “+” values were considered as equivalent to absolute
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whole numbers (e.g., “+” corresponded to 1; “++” corresponded to 2, and so on). Statistical
significance was set at p < 0.05.
Table 2. Semi-quantitative grading scale used in the present study.
Assigned Value In-Lab Criteria Used for Assignment of Value Interpretation
Immunohistochemistry (IHC)
0 No cells with a positive reaction were detected in the visual field -
+ Few cells with a positive reaction were detected in the visual field -
++ Moderate number of cells with a positive reaction were detected in the visual field -
+++ Numerous cells with a positive reaction were detected in the visual field -
++++ Abundant cells with a positive reaction were detected in the visual field -
Chromogenic In-Situ Hybridization (CISH)
0 1 to 5 green signals (copies) per nucleus detected in the cells No amplification
+ 5 to 6 green signals (copies) per nucleus detected in the cells Low-level amplification
++ 6 to 10 green signals (copies) per nucleus detected in the cells Moderate-level amplification
+++ >10 green signals (copies) detected in the cells High-level amplification
++++ Large cluster of green signals (copies) per nucleus detected in the cells High-level amplification
3. Results
3.1. Immunohistochemistry Analysis
As shown in Figure 1 and Table 3, low to moderate numbers of epithelial cells in
the tissue demonstrated bFGF, FGFR1, and FOXE1 protein expression (mean IHC semi-
quantitative grade: 1.2+, 1.4+, and 1.5+, respectively). All three proteins, however, showed
high variation in expression amongst the patients, as evidenced by the high coefficient of
variation (CV%). In the connective tissue, expression of bFGF and FGFR1 was undetectable,
with only a few cells showing a positive reaction (except in patients 3 and 8). In contrast,
FOXE1 expression was seen in numerous cells, with small variation amongst the patients
(CV% = 29%).
None of the endothelial cells showed a positive reaction for FGFR1 protein in any
of the patients while bFGF protein was evident only in a few cells. A high abundance of
cells showed positive reaction for FOXE1 in the endothelium (mean IHC semi-quantitative
grade: 3.75+). Further, expression of FOXE1 protein was also found to be the least variable
(low CV%) amongst patients, indicating its near-universally high positive reaction in
endothelial cells.
Kruskal–Wallis ANOVA post hoc analysis revealed that there were significant differ-
ences in the number of cells expressing FGFR1 and FOXE1 proteins amongst the three cell
types (Figure 2B,C). A significantly greater number of both connective tissue and epithelial
cells showed positive reactions for FGFR1 compared to the endothelial cells (p = 0.018 and
< 0.001, respectively). For FOXE1, a significantly higher number of epithelial cells showed
positive reactions compared to both connective tissue and endothelial cells (p = 0.028 and
< 0.001, respectively). No significant differences were obtained for the number of cells
positive for bFGF protein expression amongst the tissue types (Figure 2A).
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Figure 1. Expression patterns of various proteins as shown by immunohistochemical staining in lip mucosal tissue ob-
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connective tissue. Expression of bFGF in the epithelium shown by (A) none of the cells (0) and (B) a moderate number of 
cells (++). Connective tissue in both patients (A,B) showed no expression (0) of bFGF. Expression of FGFR1 in the epithe-
lium shown by (C) none of the cells (0) and (D) a moderate number of cells (++). In connective tissue, both patients (C,D) 
presented numerous cells (+++) showing expression of FGFR1. Expression of FOXE1 in the epithelium shown by (E) none 
of the cells (0) and (F) numerous cells (+++). However, in connective tissue, patient 3 (E) showed few positive cells (+) while 
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grade: 3.75+). Further, expression of FOXE1 protein was also found to be the least variable 
Figure 1. Expression patterns of various proteins as shown by immunohistochemical staining in lip mucosal tissue obtained
from patient 3 (A,C,E) and patient 8 (B,D,F) at 200×magnification. “Epi” denotes epithelium while “CT” denotes connective
tissue. Expression of bFGF in the epithelium shown by (A) none of the cells (0) and (B) a moderate number of cells (++).
Connective tissue in both patients (A,B) showed no expression (0) of bFGF. Expression of FGFR1 in the epithelium shown
by (C) none of the cells (0) and (D) a moderate number of cells (++). In connective tissue, bot patients (C,D) presented
num rou cells (+++ showing expression of FGFR1. Expression of FOXE1 in he epithelium shown by (E) none of the cells
(0) and (F) numerous cells (+++). However, in connective tissue, patient 3 (E) showed few positive cells (+) while patient 8
(F) showed numerous positive cells (+++) for FOXE1.
Table 3. Results by patient (semi-quantitative grading scale) for the IHC staining.
Patient Number
Epithelium Connective Tissue Endothelium
bFGF FGFR1 FOXE1 bFGF FGFR1 FOXE1 bFGF FGFR1 FOXE1
1 + ++ + + 0 ++++ + 0 ++++
2 + + + + + ++++ + 0 ++++
3 0 0 0 0 +++ + 0 0 ++
4 + + ++ + + ++++ + 0 ++++
5 ++ ++ + + + ++++ ++ 0 ++++
6 + ++ +++ + + +++ ++ 0 ++++
7 ++ ++ +++ 0 0 ++ + 0 +++
8 ++ ++ +++ 0 +++ +++ + 0 ++++
9 + ++ + + + +++ + 0 ++++
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Table 3. Cont.
Patient Number
Epithelium Connective Tissue Endothelium
bFGF FGFR1 FOXE1 bFGF FGFR1 FOXE1 bFGF FGFR1 FOXE1
10 + + 0 + 0 +++ ++ 0 ++++
11 ++ ++ +++ ++ + +++ ++ 0 ++++
12 0 0 0 0 0 +++ + 0 ++++
Mean 1.17 1.42 1.50 0.75 1.00 3.08 1.25 0.00 3.75
SD * 0.72 0.79 1.24 0.62 0.45 0.90 0.62 0.00 0.62
CV% ** 62.0 56.0 83.0 83.0 45.0 29.0 50.0 0.00 17.0
* SD—standard deviation; ** CV%—coefficient of variation (rounded off in percent) calculated as the ratio of the standard deviation and
mean. Note that the mean was calculated in terms of the number of pluses, i.e., in semi-quantitative terms.
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Figure 2. t i ti f i- antitative grading for I C staining for ( ) bFGF, (B) F FR1, and ( ) E1. e j ste
P values indicate ere obtai e si t t t t fr t r s l al is A test. n interpretatio of the
grading scale is sho n in Table 2.
3.2. Chro ogenic In-situ ybridization nalysis
As sho n in Figure 3 and Table 4, zero to low levels of amplification were observed for
FGFR1 and FGFR2 in the epithelial tissue (mean CISH semi-quantitative grade: 0.67+ and 0.75+,
respectively). However, the level of amplification was not uniform across the patients and
varied greatly, indicating the role of other potential influencing factors (CV% > 100%). In
the connective tissue, FGFR1 demonstrated a low level of amplification while FGFR2 demon-
strated no amplification.
In the endothelium, almost no amplification was noted for both FGFR1 and FGFR2.
No amplification was detected for FOXO1 in any of the three tissues. Further, the Kruskal–
Wallis test showed no significant difference in amplification levels of FGFR1 and FGFR2
between the three cell types (p = 0.0583 and 0.0581, respectively). Significant differences in
amplification levels amongst the cells were noted for FOXO1 (p = 0.0415).
3.3. Correlation Analysis.
With regard to the immunohistochemistry results, FGFR1 in connective tissue showed
a significant (p < 0.05) and very strong positive correlation with bFGF in connective tissue
(ρ = 0.762) and FOXE1 in endothelial cells (ρ = 0.771), while a strong positive relationship
was noted with FOXE1 in connective tissue (ρ = 0.668). As shown in Figure 4, in the
epithelium all three proteins showed very strong significant positive correlations with each
other (bFGF–FGFR1 with ρ = 0.775; bFGF–FOXE1 with ρ = 0.725; and FOXE1–FGFR1 with
ρ = 0.720). A strong positive correlation was observed for bFGF in connective tissue and the
endothelium (ρ = 0.645). A very strongly association was found for FOXE1 in connective
tissue and the endothelium (ρ = 0.708).
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Figure 3. Expression of various genes as shown by chromogenic in-situ hybridization (CISH) in lip mucosal tissue at 1000×
magnification (visualized using immersion oil). Amplification was visualized through the number of green signals (dots)
per nucleus per cell. (A,B) Moderate amplification (++) was found for levels of FGFR1 in the epithelium in patients 2 and 5,
res ectively. (C) Weak amplification (+) and (D) no amplification (0) were found for levels of FGFR2 in the epithelium in
patients 9 and 1, respectively. (E,F) No amplification (0) was found for levels of FOXO1 in the epithelium in patients 8 and
12, respectively.
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Table 4. Results by patient (semi-quantitative grading scale) for the CISH analysis.
Patient Number
Epithelium Connective Tissue Endothelium
FGFR1 FGFR2 FOXO1 FGFR1 FGFR2 FOXO1 FGFR1 FGFR2 FOXO1
1 0 0 0 0 0 0 0 0 0
2 ++ ++ 0 ++ + 0 0 0 0
3 0 + 0 0 0 0 0 + 0
4 0 0 0 0 0 0 0 0 0
5 ++ ++ + + + 0 0 0 0
6 0 0 0 0 0 0 + 0 0
7 + + + 0 0 0 0 0 0
8 + 0 0 ++ + 0 0 0 0
9 + + 0 + + 0 0 0 0
10 + 0 + + 0 0 + 0 0
11 + ++ 0 + + 0 0 0 0
12 0 0 0 0 0 0 0 0 0
Mean 0.75 0.75 0.25 0.67 0.42 0.00 0.17 0.08 0.00
SD * 0.74 0.87 0.45 0.78 0.51 0.00 0.39 0.28 0.00
CV% ** 99.0 116.0 180.0 116.0 121.0 0.00 229.0 350.0 0.00
* SD—standard deviation; ** CV%—coefficient of variation (rounded off in percent) calculated as the ratio of the standard deviation and
mean. Note that the mean was calculated in terms of the number of pluses, i.e., in semi-quantitative terms.
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In regard to the chromogenic in-situ hybridization results, a strong to very strong
positive correlation was observed between FGFR1 in epithelial cells and FGFR2 in both
epithelium and connective tissue, respectively (ρ = 0.596 and 0.855, respectively). Further,
FGFR1 in the epithelium was also very strongly correlated with FGFR1 in connective
tissue (ρ = 0.821). A similar observation was noted for FGFR2 in the epithelium and
connective tissue (ρ = 0.637). In connective tissue, both FGFR1 and FGFR2 were also very
strongly associated (ρ = 0.767). Utilizing both the CISH and IHC results, a very strong and
significant negative correlation was observed between FOXE1 and FGFR2 in endothelial
cells (ρ = −0.739). Similarly, a strong positive association was noted for bFGF and FGFR1
(CISH) in endothelial cells (ρ = 0.590).
4. Discussion
A multifactorial pathoetiology combined with high incidence and translated down-
stream high socio-economic burden makes orofacial clefts of particular interest to various
research groups working to elucidate the factors/cellular pathways that play a role in
pathogenesis of clefts. Understanding these interactions, which can range from gene–gene
(GxG) to gene–environment (GxE), is crucial for creating models and systems that can
aid in predication, diagnosis, prognosis, and treatment of cleft pathology. Over 70% of
cases of cleft lip and palate are non-syndromic while the remainder comprise of syndromic
cases and of those syndromes that usually arise secondary to chromosomal or teratogenic
effects [11]. The etiology of syndromic forms is traceable by genetic analysis, which reveals
the underlying genetic mutation responsible. However, in cases of isolated, non-syndromic
clefts, the gene–environment interactions (GxE), which are thought to be the main reasons
for clefting, are difficult to confirm. This warrants a search for possible gene–gene interac-
tions (GxG) and their interactions with environmental teratogens in order to isolate the
underlying cause of clefting [32].
4.1. Fibroblast Growth Factor Receptor 1 (FGFR1)
The FGF/FGFR signaling genes are expressed in a spatiotemporally specific manner
in the palatal tissue and constitute a directional regulatory axis between the stromal and
epithelial compartments [8,17]. FGFR1, which is highly expressed in the CNC-derived
connective tissue (mesenchyme) in the palatal shelf, is usually responsible for mediating
epithelium-to-mesenchyme signaling while FGFR2 mediates the reciprocal communication
(hence FGFR2 is more abundant in the epithelium). In a study on mice conducted by
Wang et al. [8], the authors demonstrated that ablation of FGFR1 in NCCs delayed (not
inhibited) cellular proliferation of both the mesenchyme and epithelium and impeded
development of medial nasal processes. Further, they reported impeded elevation of palatal
shelves prior to midline fusion (a key event in normal palatogenesis). Additionally, FGFR1
was also shown to play an important role in controlling MEE degeneration during palate
fusion [8]. In contrast, it has also been shown that increased expression of FGFR1 leads to
increased cellular proliferation in the palate shelves and cleft palate [33].
Therefore, both excess and deficiency of FGFR1 signaling leads to clefting and a
precise balance in protein and gene expression are needed for normal palatogenesis. In the
endothelium, FGFR1 plays a key role in inhibiting the endothelium–mesenchyme transition
(EndMT) via the inhibition of TGFβ/Smad signaling pathway, thereby preventing tissue
fibrosis and maintaining a normal state of vascularity [34]. Further, loss of endothelial
FGFR1 and FGFR2 has been shown to result in impaired neovascularization after injury in
adult mice [35]. FGFR1 has also been shown to be widely expressed in the myofibroblasts of
injured palates, suggesting that FGFR1 signaling is also important for palate repair during
injury [8,36]. Finally, it has been demonstrated that disruption of FGFR1 signaling reduces
local inflammation by restraining activation of the NF-κB signaling cascades [37,38]. Clearly,
FGFR1 plays a key role in maintaining normal development processes and in preventing
fibrosis and inflammation.
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Overall, our IHC and CISH results indicate that more FGFR1 receptors are present
in epithelial cells, followed by connective tissue cells, and none in the endothelial cells.
The presence of elevated expression of FGFR1 in cleft epithelium thus, leads to increased
cellular proliferation that may lead to clefting and local site inflammation. This is in line
with our previous studies in which we demonstrated moderate expression of proliferation
marker Ki67 in epithelial cells from cleft tissue (compared with no Ki67 expression in
control samples) [39].
Further, the fact that FGFR1 was not detected in the endothelium indicates its potential
role in promoting fibrosis [34]. This finding potentially also correlates clinically with the
post-operative complications, like slow healing and hypertrophic scars, that are frequently
reported in cleft patients [40]. Further, elevated expression of FGFR1 leads to a significant
decrease in TGFβ1 expression, a potent anti-inflammatory and immunosuppressive factor,
which brings our findings in line with those of our previous study [41].
4.2. Fibroblast Growth Factor Receptor 2 (FGFR2)
FGFR2, another associated FGF receptor, is primarily expressed in the developing
palatal epithelium that binds FGF10, a factor known to be localized in the adjacent underly-
ing mesenchyme [42]. Deficiency of either FGFR2 or FGF10, or both, leads to clefting and a
thin epithelium due to the severe reduction in cell proliferation [42]. Since FGF10/FGFR2
signaling affects the epithelium, there is a lack of FGFR1-mediated reciprocal signaling from
the epithelium, which consequently leads to proliferation defects in the mesenchyme [42].
Further, loss of FGFR2 has been shown to compromise the organization of the rugae (the
thickened lines on the secondary palate) [43]. FGFR2 has two main epithelial isoforms,
namely FGFR2b and FGFR2c. While FGFR2b has been associated with tumor suppression,
amplification of FGFR2c has been linked with various epithelial tumors [44,45]. Further, it
has been shown that an abnormal switch from FGFR2b to the FGFR2c isoform could be the
main triggering event leading to epithelium-to-mesenchyme transition (EMT) in normal
human keratinocytes [46].
In a study on human keratinocyte cell line HaCaT, Ranieri et al. concluded that
increased expression of FGFR2c leads to morphological and cytoskeletal changes, gene
reprogramming, and invasive behavior, reminiscent of type III EMT (seen in carcinogenesis
in which epithelial cells may completely lose their vestiges and become fully mesenchy-
mal) [45]. Further, higher expression of FGFR2b has been associated with physiological
type II EMT (seen in adult tissue regeneration). Since our FGFR2 CISH probe could not
distinguish between the two isoforms, it was difficult to conclude, for patients 2, 5, and 11,
who showed moderate amplification, and patients 7 and 3, who showed low amplification
in the epithelium, which splicing isoform was more abundant and, hence, the type of
EMT. Therefore, we can conclude that FGFR2 in general demonstrates a specific expression
pattern and that more intensive studies investigating the role of FGFR2 isoforms are needed
to further our understanding in predicting the clinical course of clefts.
4.3. Basic Fibroblast Growth Factor/Fibroblast Growth Factor 2 (bFGF/FGF2)
bFGF has been described as a biological mediator that regulates connective tissue
cell migration, proliferation, and synthesis of intracellular proteins and extracellular
matrix [47,48]. It has been shown to induce angiogenesis via VEGF (vascular endothelial
growth factor) in vitro [49], while in vivo it has been demonstrated to accelerate the healing
process [50]. Additionally, Choi et al. found that bFGF suppressed collagen type I genera-
tion and subsequent scar tissue formation [48]. Like FGFR2b, bFGF has also been associated
with the potential to accelerate type II EMT, thereby promoting wound closure [51]. Eleva-
tion of bFGF levels in our patients was in line with previous findings in which bFGF was
reported to be increased in concentration in the serum and affected tissue of patients with
chronic inflammation and rheumatoid arthritis [52,53]. bFGF has been shown in vivo to
enhance the recruitment of monocytes, T cells (due to elevated IFN-γ (interferon gamma)),
and PMN (polymorphonuclear) cells in response to elevated TNF-α (tumor necrosis factor
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alpha) and IFN-γ [52]. These findings are in line with our previous study in which we
reported elevated TNF-α and IFN-γ levels [41], indicating that pro-inflammatory cytokines
mediate their inflammatory effects via elevation of bFGF in cleft tissue. Thus, our findings
also indicate that bFGF, along with other factors, induces inflammatory and immune cell
recruitment, which chronically leads to an angiogenic environment (supported by results
showing elevated bFGF protein expression in endothelium from IHC) [41,52].
4.4. Potential Roles Mediated By FGF/FGFR Family Genes in Cleft Lip/Palate Pathogenesis
It has been reported that the bFGF/FGFR1 axis can exert an anti-inflammatory response
in astrocyte-mediated neuroinflammation, especially after infrasound exposure [54]. How-
ever, other authors have reported that the axis exerts a pro-inflammatory effect [38,40,55].
Hence, in the case of orofacial clefts, we postulate that this axis indeed exerts a pro-
inflammatory effect. The elevated expression of FGFR1 and bFGF and the high correlation
between them in the epithelium, connective tissue, and endothelium cells supports our
hypothesis. The correlation indicates a positive feedback loop between them, as previously
it has been demonstrated that bFGF can upregulate the expression of FGFR1 on astro-
cytes [54]. It has also been shown that endothelial cells can be stimulated to produce and
release bFGF by pro-inflammatory mediators like IFN-γ in combination with IL-2, IL-1β,
and nitric oxide (NO) [56,57]. This creates a vicious cycle whereby damaged mucosal tissue
(due to improper palatal closure, shear stress, or shock) secretes IFN-γ, TNF-α, IL-2, and so
on, which upregulate bFGF, which then upregulates FGFR1 protein expression that then
recruits PMNs, T cells, and so on. These cells, in turn, secrete more bFGF [58,59] which
sustains inflammation (via FGFR1) and angiogenesis (via FGFR2) at the cleft site, leading
to chronic inflammation and fibrotic changes and tissue scarring.
We expected that in almost half of our patients—those with no detectable FGFR2
amplification (patients 1, 4, 6, 8, 9, 10, and 12)—there would be low or zero amplifica-
tion/protein levels for FGFR1 since the crosstalk was impaired. However, our findings
regarding FGFR1 amplification and the moderate number of cells expressing FGFR1 protein
confirm the possible amplifying role of bFGF in FGFR1 expression and the importance of
these receptors in the pathogenesis of clefts. Additionally, hypoxia has been associated with
the pathogenesis of cleft lip and palate; however, the exact mechanism is not yet known.
Recently, polymorphisms of the HIF-1A (hypoxia inducible factor 1A) gene were ruled out
as a cause of clefting [60]. We propose that hypoxia-induced clefting is probably rather
related more directly with the FGF/FGFR signaling pathway (this needs further validation).
Conte et al. found that, in the early hypoxia phase, bFGF upregulation does not occur at
the mRNA level but at the protein level. This upregulation (in vascular smooth muscle
cells) is due to increased ribosomal translational activity via IRES (internal ribosome entry
site, a transcriptional regulator) rather than HREs (hypoxia response elements), which
are used by HIF-1A to regulate bFGF expression [61]. However, in later stages of hypoxia,
bFGF induces HIF-1A protein expression which then regulates bFGF expression (via HREs),
thereby creating an autocrine amplification loop [62].
Interestingly, hypoxia along with cell damage and fluid/plasma protein exudation can
also manifest as an effect of clefting in tissue due to chronic inflammation. Hypoxia can in-
crease the sensitivity of endothelial cells via increased HSPG (heparan sulfate proteoglycan)
synthesis in endothelial cells [63] along with increased bFGF production by vascular peri-
cytes [64]. Finally, regarding angiogenesis induced by the bFGF/FGFR2 pathway, although
autocrine amplification has been reported [65], its implications and effects are relatively un-
known. Additionally, negative regulators that bind excessive bFGF have also been reported.
PF4 (platelet factor 4) and PTX3 (pattern recognition receptor pentraxin 3, synthesized in
response to TNF-α and IL-1β) both bind bFGF, leading to its decreased interaction with
FGFR1/2 [66,67]. In fact, the roles of PTX3 and PF4 in cleft lip and palate have never been
reported before and we suggest this as a potential new avenue for investigation since they
modulate the binding of bFGF with its receptors.
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4.5. Forkhead Box Protein E1/Thyroid Transcription Factor 2 (FOXE1/TTF2)
Also known as thyroid transcription factor 2 (TTF2), FOXE1 is usually expressed in
later stages of development in tissues derived from pharyngeal arches and the pharyngeal
wall, including the thyroid, tongue, epiglottis, palate, and esophagus [68]. Further, it has
been shown to be co-expressed with Shh (sonic hedgehog) in these tissues, usually around
the same time, and to mediate the epithelial–mesenchymal crosstalk [68]. Recently, analysis
revealed that amplification of FOXE1 affects MSX1 and TGF-β3 downstream in the exertion
of its action in the cleft tissue [69]. Interestingly, both these targets are found to be abundant
at the sites where epithelial–mesenchymal interactions take place, including the cellular
primordia involved in craniofacial morphogenesis [69,70]. To add to this, MSX1 is another
commonly associated gene with isolated non-syndromic clefts [21,22]. TGF-β3, on the other
hand, is expressed in the MEE of pre-fusion shelves, with its expression decreasing shortly
after the midline epithelial seam is formed [69,71].
It has been shown in thyroid tissue that FOXE1 regulates the activity of NR4A2 (nu-
clear receptor subfamily 4 group A member 2). The authors showed that there is an indirect
regulation between FOXE1 and NR4A2 whereby silencing of FOXE1 leads to downregu-
lation of NR4A2 [72]. The gene NR4A2 belongs to the family of ligand-independent early
response genes, which are involved in proliferation, apoptosis, and inflammation and have
been demonstrated to enhance migration of mesenchymal stromal cells [73]. Additionally,
it has been shown that TGF-β1/2 significantly downregulates the expression of NR4A2
in palatal mesenchymal cells [74]. NR4A2 has also been shown to be induced by TNF-α,
IL-1β, and VEGF in synoviocytes, chondrocytes, endothelial cells, and immune cells [75,76].
Elevated expression of FOXE1 in our patients and the fact that VEGF can be induced by
elevated bFGF (as seen in our patients), coupled with elevated TNF-α and downregu-
lated TGF-β1 in cleft patients [41], suggests that local site inflammation is alternatively
maintained in part by upregulation of the FOXE1/NR4A2 pathway in cleft patients.
4.6. Forkhead Box Protein O1 (FOXO1)
FOXO1, another transcriptional regulator, has been shown to play a crucial role in
palatogenesis. It is needed for transcriptional promotion of the pro-apoptotic Fas ligand
(FasL)/caspase-3 pathway in MEE cells, which paves the way for correct palate fusion [77].
However, for FOXO1 to function it needs to undergo acetylation by p300 in the presence
of BAG6 (Bcl-2-associated anthanogene 6) [78]. BAG6 has also been recently described as
another candidate gene for non-syndromic clefts. Non-detection of FOXO1 amplification
in our patients indicates upstream signaling impairment which leads to clefting. BAG6
has also been shown to induce TGF-β3 transcriptional target expression [79], which shows
the complex web of interactions taking place in cleft tissue. FOXO1 also plays a crucial
role as a gatekeeper in endothelial cells. It restricts endothelial growth, thereby lowering
endothelial metabolism and supporting the function of endothelial cells [80]. This helps
the cells to consume less energy, nutrients, and O2, thereby reducing oxidative stress
in endothelial cells. Deletion of FOXO1 has been shown to cause a profound increase
in endothelial proliferation that interferes with coordinated sprouting, thereby causing
hyperplasia and vessel enlargement [80]. Hence, no to low amplification of FOXO1 (as
seen in our patients) leads to increased oxidative stress and damage in the cells, leading to
promotion of inflammatory changes in the tissue.
4.7. Clinical Diagnostic Techniques and Advances for Cleft-Affected Patients
Cleft lip and/or palate have been reported to be associated with aplasia of the salivary
glands, which leads to xerostomia, multiple dental caries, and early tooth loss [81,82]. The
characteristics of the tissue replacing the defective sites can also be evaluated without
surgical intervention using ultrasound, CT, MRI, or FNA (fine needle aspiration) [83].
Since salivary glands and the oral epithelium share the same ectodermal origin, it has
been demonstrated that genes involved in clefting are also expressed in ductal epithelium
during embryogenesis [84–86]. Further, it has been reported that the absence of FGFR2b is
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associated with an absence of salivary glands in mouse models [87]. Since more than half
of our patients did not show detectable amplification of FGFR2b, it would be interesting to
further study and investigate the salivary gland tissue in cleft-affected patients.
Further, with the advent of new modern technologies, like microtomography and
peripheral quantitative computed tomography (pQCT), it is easier than ever to precisely
map and reconstruct in 3D the morphology of the oral structures, both quantitatively
and qualitatively [88]. Such techniques could, in the future, have the potential to aid and
predict the outcome and severity of clefting, as well as predict the outcomes of treatments,
i.e., post-operative complications like inflammation, scarring, and so on. Other digital
techniques, like CAD/CAM technology and intra-oral digital scanners, can aid in the
appropriate diagnostics and management of cleft-affected patients [89,90].
These techniques are more efficient compared to conventional impression modeling
techniques since they get rid of the need to send impression models physically. A single
electronic file can be sent to laboratories for investigation, thereby saving time, resources,
and space. They also eliminate distortions as well as volumetric variations related to
impression material [91,92].
4.8. Surgical Management of Cleft-Affected Patients
The main aim of surgical management is the early reconstruction of normal anatomy
to allow for physiologic growth of the midface structures and enable children to develop
undisturbed mastication, speech, hearing, and esthetics [93,94]. The generally accepted
time for intervention has historically been reported as 10 weeks (2.5 months) after birth,
since earlier intervention risks increased chances of post-operative complications during
the neonatal period [95]. Advances in neonatal care and technology have made it possible
to provide surgical care even at earlier stages (within the first 28 days post-birth) [96];
however, no significant differences have been reported in terms of cosmetic attraction or
the success of the surgical outcome, even when the surgery is not done in the neonatal
period [97]. For patients with clefting of the hard palate, the optimal time of surgery is
within 18 months post-birth, since repair at later stages, i.e., beyond three years of age,
has been associated with severely restricted language development and stereotyped cleft
speech characteristics [95,98].
Cleft-affected patients usually undergo reconstruction of the alveolar ridge (gingiva-
peri-osteoplasty) in combination with closure of the lip. However, despite this, 60–80% of
patients require a second bone graft or sinus lift to allow for implant placement [93]. In
these patients, apart from plastic surgery, it is important to preserve the bone volume along
with augmentation of the vertical aspect of the bone. This could be followed by localized
sinus elevation with minimal surgical trauma, thereby increasing the available bone for
implant placement [99–101]. The crestal bone is displaced toward the sinus floor and the
apical portion of the implant is placed in the augmented space [99–101]. Additionally,
human maxillary sinus membrane tissue represents a potential source of multipotent
mesenchymal stem cells that can promote a natural healing process [99,102,103]. Further,
since the incidence of missing teeth in cleft patients is close to sixfold higher than in non-
cleft patients, insertion of endosseous dental implants to replace missing teeth is greatly
preferred [93,104–106]. Finally, maintenance of oral hygiene is of high importance in such
patients to prevent the inserted implant from failing and to prevent systemic spread of
infection from the oral cavity [107–109].
4.9. Relevance and Limitations of the Present Study
The main aim of the present study was to explore and understand the expression
levels of FGF/FGFR and FOX family proteins in tissue from cleft-affected children. Firstly,
the expression analysis of these genes allows an understanding of their role in promoting
post-operative complications, like scarring, inflammation, and fibrosis. Secondly, since
cleft lip and palate is a hereditary condition, gathering knowledge about the chances of the
gene being passed on in a family and the nature and severity of the condition caused by
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the causative genes is inevitably a genuine concern for affected families. Hence, evaluation
of such genes enables us to be better positioned to predict the heritability and the course of
the manifestation of the clefting. Thirdly, since humans are diphyodonts (i.e., have two sets
of dentitions—primary and permanent), it is of utmost importance to understand the gene
expression of these genes in cleft-affected tissues, since 60–80% of cleft patients regularly
require more than two rounds of corrective surgery and the incidence of missing teeth in
cleft children is nearly six times higher than in non-cleft children [93,104–106].
Nonetheless, the present study has its limitations, including the limited number of
patients studied and the lack of control samples. However, we must point out that the
number of studies on human tissue is limited due to the non-availability of tissue material.
This is understandable, especially since tissue material needs to be taken during surgery,
which happens at a very tender age and is accompanied by genuine parental concerns.
Further, decisions regarding procurement of tissue from patients are made with the best
interests of patients in mind (if the obtainment of tissue is possible at all). Finally, we cannot
at this stage predict or state whether neonatal gene expression resembles embryonic gene
expression, especially at the time of palatogenesis. This is firstly because of technological
limitations and secondly because of ethical guidelines prohibiting experimentation on
human embryos. However, studies in rat models suggest that, during normal palatogenesis,
expression of the studied genes, like FGFR1 and FGFR2, is elevated before fusion of the
palate but ceases to exist after palatal plate fusion and is exhibited only by MEE cells [110].
Since it is known that MEE cells eventually degenerate due to epithelial–mesenchymal
crosstalk, it can be naturally expected that expression of these genes also ceases to exist in
palatal tissue. However, detection of such genes (at higher levels of expression) in palatal
tissue in our samples makes us to postulate that the palate failed to fuse in these cases (and
hence that the patients had clefting); thus, is the closest representation of gene expression
during the events of palatal fusion. We suggest that future studies should investigate
phenotypic and molecular data from animal models to further bolster our findings.
5. Conclusions
The complex myriad of interactions between various factors and environmental terato-
gens discussed above needs more investigation and in-depth studies. The most significant
findings of the present study can be summarized as follow:
1. Elevated expression of FGFR1 in cleft epithelium indicates its role in mediating cellular
proliferation and local site inflammation. No to low expression in the endothelium
indicates its role in fibrosis. Coupled together, this indicates that FGFR1 expression
can help in predicting the sequalae and intensity of post-operative complications
like scarring.
2. bFGF (or FGF2) elevation may induce local site inflammation (via FGFR1) which
chronically leads to creation and promotion of an environment suitable for angiogenic
activity (via FGFR2). Additionally, over-amplification of FGFR2 in some patients points
to its possible disordered role in epithelial–mesenchymal transition in cleft patients.
3. High expression of FOXE1 possibly exerts a pro-inflammatory effect via involvement
of the NR4A2/VEGF pathway (also induced by bFGF), while the lack or low level of
amplification of FOXO1 can lead to retention of the midline epithelium coupled with
increased endothelial oxidative stress and tissue inflammation.
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